Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Immune Checkpoint Bioassays

Our industry leading bioassays can accelerate your immunotherapy drug development. Whether you’re targeting immune checkpoint co-inhibitory, co-stimulatory, or a combination of receptors, we have the tools to meet your needs. Our robust collection of assays can be used in a variety of settings, from antibody screening and characterization, to potency and stability determination and QC lot release.  

Save 20% on Detection Instruments to Optimize Your Assays ›

Filter By


Immune Checkpoint Bioassays

Shop all Immune Checkpoint Bioassays

Showing 12 of 12 Products

An Introduction to Immune Checkpoint Receptors

The immune system is comprised of a complex network of co-inhibitory and co-stimulatory pathways that help to maintain homeostasis and prevent autoimmunity. Under typical conditions, these immune checkpoints allow appropriate immune response to infections and malignancies while protecting healthy tissues from harm. 

Inhibitory immune checkpoint receptors (including PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3) expressed on activated T cells and B cells play a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of a receptor by its ligand on an adjacent cell inhibits T-cell receptor (TCR) signaling and TCR-mediated proliferation, transcriptional activation and cytokine production. Therapeutic antibodies and Fc fusion proteins designed to block the receptor-ligand interaction show promising results in clinical trials for the treatment of a variety of cancers.

Co-stimulatory immune checkpoint receptors (including GITR, OX40, CD40, 4-1BB, and ICOS) are expressed on T cells. Therapeutic antibodies designed to activate these immune checkpoint receptors and enhance immune signaling are also emerging as a promising strategy for cancer therapy. 

Cell-based functional reporter bioassays are critical to the development and characterization of antibody based biologic drugs targeting immune checkpoint receptors.